Genmab A/S (GMAB) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Genmab A/S (GMAB) over the past year, gaining 11.7% versus a gain of 10.1%. Over five years, MIRM leads with a +375.2% price change compared with -18.9% for GMAB. Genmab A/S is the larger company by market cap ($22.70 billion vs $5.56 billion), about 4.1 times the size, while Mirum Pharmaceuticals is growing revenue faster (+54.7% vs +19.2%).
Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -4.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | MIRM |
|---|---|---|
| Share price | $36.91 | $85.65 |
| Market cap | $22.70B | $5.56B |
| 1-day change | +2.39% | +5.29% |
| YTD return | +17.05% | +2.99% |
| 1-year return | +10.11% | +11.67% |
| 5-year return | -18.86% | +375.18% |
| P/E ratio (TTM) | 29.06 | — |
| Forward P/E | 24.20 | — |
| EPS (TTM) | $1.27 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $521.31M |
| Revenue growth (YoY) | +19.19% | +54.74% |
| Net income (latest FY) | $963.00M | $-23.36M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | -4.25% |
| Net margin | 25.89% | -4.48% |
| 52-week high | $40.17 | $130.00 |
| 52-week low | $23.62 | $63.23 |
| Distance from 52-week high | -8.12% | -34.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.10% | +70.22% |
| Average volume | 2.83M | 695.76K |
| Shares outstanding | 614.90M | 64.93M |
| Employees | 3,119 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.1 times larger than Mirum Pharmaceuticals by market value ($22.70B vs $5.56B).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -4.5 cents for Mirum Pharmaceuticals.
- Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs +19.19%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
GMAB vs MIRM FAQ
Which is bigger, Genmab A/S or Mirum Pharmaceuticals?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.70B compared with $5.56B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, GMAB or MIRM?
MIRM returned +11.67% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Genmab A/S and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.